Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group
- 408 Downloads
Following the introduction of rituximab, the long-term overall survival (OS) rate of advanced-stage follicular lymphoma (FL) cases was expected to improve after the introduction of rituximab: however, there is a lack of large-scale survey data in Asia due to the relatively low incidence of FL. We conducted a retrospective survey to assess the treatment outcomes in patients with newly diagnosed advanced-stage FL in 29 institutions in Hokkaido from January 2001 to December 2010. The total number of patients was 443 (men 47.6 %, women 52.4 %), with a median age of 55 years (range 20–80 years). Of the cases examined, 42.2 % had stage III and 57.8 % had stage IV disease. Furthermore, 62.5, 19.7, 9.2, 5.2, and 3.4 % had performance statuses of 0, 1, 2, 3, and 4, respectively. The 5-year OS was 91.2 %, and no survival plateau was observed. Seventeen patients experienced secondary malignancies (six hematological diseases and 11 solid cancers; 5-year probability, 4.2 %). Eighteen patients experienced transformation (5-year probability, 4.5 %). The overall survival at 5 years after therapy for transformation was 50 %. Before the introduction of rituximab, the 5- to 10-year OS of advanced-stage FL patients in Japan was reported to be about 30–60 %. Although these data are limited, improvement in OS has been observed in Japan during the rituximab era.
KeywordsFollicular lymphoma Rituximab Long-term survey Hokkaido Hematology Study Group Overall survival
The authors thank Kiyohiko Hatake for the helpful advices.
- 1.The non-Hodgkin’s lymphoma Classification Project. A clinical evaluation of International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood. 1997;89:3909–15.Google Scholar
- 3.Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–32.PubMedCrossRefGoogle Scholar
- 6.Tobinai K, Ogura M, Itoh K, Kinoshita T, Hotta T, Watanabe T, et al. Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow up results. Cancer Sci. 2010;101:2579–85.PubMedCrossRefGoogle Scholar
- 9.Basic resident register in Japan. http://www.stat.go.jp/data/idou/2011np/kihon/pdf/gaiyou.pdf.
- 10.Torimoto Y, Sato K, Ikuta K, Hayashi T, Hirayama Y, Inamura J, et al. A retrospective clinical analysis of Japanese patients with peripheral T-cell lymphoma not otherwise specified: Hokkaido Hematology Study Group. Int J Hematol. 2013;98(1):71–8.Google Scholar
- 12.Onozawa M, Hashino S, Haseyama Y, Hirayama Y, Iizuka S, et al. Incidence and risk of post herpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: Hokkaido Hematology Study Group. Biol Blood Marrow Transplant. 2009;15:724–9.PubMedCrossRefGoogle Scholar
- 14.Brice P, Bastion Y, Lepage E, Brousse N, Haïoun C, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1997;15:1110–7.PubMedGoogle Scholar
- 19.Kahl B. Is there a role for “watch and wait” in follicular lymphoma in the rituximab era? Hematology Am Soc Hematol Educ Progr. 2012;2012:433–8.Google Scholar
- 20.Niitsu N, Umeda M. Prognostic factors of follicular lymphoma treated with combination chemotherapy. Jpn J Clin Hematol. 1997;38:496–504.Google Scholar
- 21.Hiroo K. Clinical studies on 53 cases of follicular lymphomas. Tokyo Jikei Med J. 1993;108:11–30.Google Scholar
- 22.Toshyyuki T, Kazumi S, Umihiro S, et al. Follicular lymphoma in Japan: retrospective study on natural history and therapeutic results in 50 cases collected from 4 institutions. Jpn J Clin Oncol. 1989;30:2123–8.Google Scholar
- 26.Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008;111:4004–13.PubMedCrossRefGoogle Scholar
- 27.Gyan E, Foussard C, Bertrand P, Michenet P, Le Gouill S, Berthou C, et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood. 2009;113:995–1001.PubMedCrossRefGoogle Scholar
- 28.Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:2667–74.PubMedCrossRefGoogle Scholar
- 29.Ogura M. Recent therapeutic progress in non-Hodgkin lymphoma: focusing on diffuse large B-cell lymphoma and follicular lymphoma. Jpn J Clin Hematol. 2008;49:1434–50 (in Japanese).Google Scholar
- 31.Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001;98:3595–9.PubMedCrossRefGoogle Scholar
- 32.Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555–62.PubMedCrossRefGoogle Scholar
- 36.Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013;31:3272–8.PubMedCrossRefGoogle Scholar